Overlapping effects of genetic variation and epigenetics on drug response: Challenges of pharmacoepigenomics

Pharmacogenomics

Volumn 14, Issue 15, 2013, Pages 1807-1809

  Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Epigenetics; MiRNA; Pharmacogenetics; Systems biology

Indexed keywords

AZACITIDINE; CARBAMAZEPINE; DNA; IMATINIB; METHOTREXATE; RIFAMPICIN; VALPROIC ACID;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; DRUG RESPONSE; EDITORIAL; EPIGENETICS; GENE EXPRESSION; GENETIC TRAIT; GENETIC VARIABILITY; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHARMACODYNAMICS; PHARMACOEPIGENOMICS; PHARMACOGENOMICS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIGENESIS, GENETIC; GENETIC VARIATION; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS;

EID: 84893464176     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.194     Document Type: Editorial

References (22)

1. Becquemont L, Alfirevic A, Amstutz U et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on pharmacogenetics and pharmacogenomics. Pharmacogenomics 12(1), 113-124 (2011).
2. Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem. Immunol. Allergy 97, 18-31 (2012).
3. Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin. Pharmacol. Ther. 92(6), 727-736 (2012).
4. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 21(35), 5400-5413 (2002). (Pubitemid 34983477)
5. Schaeffeler E, Hellerbrand C, Nies AT et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 3(12), 82 (2011).
6. Fisel P, Kruck S, Winter S et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin. Cancer Res. 19(18), 5170-5181 (2013).
7. Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin. Cancer Res. 12, 1850-1858 (2006).
8. Baker EK, Johnstone RW, Zalcberg JR, El- Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24(54), 8061-8075 (2005). (Pubitemid 41746749)
9. Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 4(4), 369-381 (2005).
10. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet. Genomics 22(3), 198-205 (2012).
11. Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol. Pharmacol. 84(5), 655-669 (2013) (Epub ahead of print).
12. Haenisch S, Laechelt S, Bruckmueller H et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol. Pharmacol. 80(2), 314-320 (2011).
13. Vlaming ML, van Esch A, van de Steeg E et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab. Dispos. 39(8), 1338-1344 (2011).
14. Puranik YG, Birnbaum AK, Marino SE et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14(1), 35-45 (2013).
15. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167, 555-564 (2010).
16. Powell TR, Smith RG, Hackinger S et al. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl. Psychiatry 3, e300 (2013).
17. Pardini B, Rosa F, Barone E et al. Variation within 3' UTRs of base excision repair genes and response to therapy in colorectal cancer patients: a potential modulation of microRNAs binding. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-13-0314 (2013) (Epub ahead of print).
18. Sebio A, Pare L, Paez D et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet. Genomics 23(3), 142-147 (2013).
19. Grimminger T, Pernhorst K, Surges R et al. Levetiracetam resistance: synaptic signatures and corresponding promoter SNPs in epileptic hippocampi. Neurobiol. Dis. 60C, 115-125 (2013).
20. Wu Y, Xiao Y, Ding X et al. A miR- 200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2 alpha gene is associated with cisplatin resistance. PLoS ONE 6(12), e29043 (2011).
21. Wang H, Tan G, Dong L et al. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 7(4), e34210 (2012).
22. Jayaraman S, Patel A, Jayaraman A, Patel V, Holterman M, Prabhakar B. Transcriptome analysis of epigenetically modulated genome indicates signature genes in manifestation of Type 1 diabetes and its prevention in NOD mice. PLoS ONE 8(1), e55074 (2013).